StockNews.AI
ARWR
StockNews.AI
126 days

Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

1. Arrowhead's CFO Ken Myszkowski will retire in May 2025. 2. Daniel Apel has been appointed as the new CFO.

2m saved
Insight
Article

FAQ

Why Neutral?

Leadership changes can introduce uncertainty. Previous leadership transitions have caused minor fluctuations but no significant long-term impacts.

How important is it?

Leadership change may affect investor confidence but is standard for companies.

Why No Impact?

CFO transitions typically do not affect stock prices immediately. Long-term effects remain to be seen depending on new strategies.

Related Companies

ARWR
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and will be succeeded by Daniel Apel, who has been appointed as the company's new Chief Financial Officer. Mr. Myszkowski will continue to serve as an employee adviser to assist and facilitate an effective transition. “Ken has been a valuable member of the Arrowhea.

Related News